Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

aché laboratórios farmacêuticos s.a - colecalciferol, Ácido ascÓrbico 90%, Ácido fÓlico, biotina, cloridrato de piridoxina, cianocobalamina 0,1%, nicotinamida, riboflavina, nitrato de tiamina, pantotenato calcico, fumarato ferroso, Óxido de magnÉsio, sulfato de manganÊs monoidratado, Óxido de zinco, mistura de iodeto de potÁssio, Óxido de cobre, cloreto de cromo, carbonato de cÁlcio, acetato de retinol, acetato de racealfatocoferol, estearato de magnÉsio - polivitaminicos com minerais

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

aché laboratórios farmacêuticos s.a - acetato de retinol, colecalciferol, Ácido ascÓrbico, Ácido fÓlico, acetato de racealfatocoferol, biotina, cloridrato de piridoxina, cianocobalamina, nicotinamida, riboflavina, mononitrato de tiamina, pantotenato calcico, fumarato ferroso, Óxido de magnÉsio, sulfato de manganÊs, Óxido de zinco, mistura de iodeto de potÁssio, Óxido de cobre, cloreto de cromo, carbonato de cÁlcio, fluoreto de sÓdio - polivitaminicos com minerais

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

actavis group ptc ehf. - metotrexato - solução injetável ou para perfusão - 25 mg/ml - metotrexato 25 mg/ml - methotrexate - n/a - duração do tratamento: longa duração

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

vitamedic industria farmaceutica ltda - ibuprofeno - analgesicos nao narcoticos

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - outros agentes antineoplásicos - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

União Europeia - português - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agentes antineoplásicos - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

blau farmacÊutica s.a. - Ácido ascÓrbico - monovitaminas exceto vitamina k

União Europeia - português - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agentes antineoplásicos - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

União Europeia - português - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agentes antineoplásicos - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

União Europeia - português - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - agentes antineoplásicos - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.